Scalper1 News
If you’ve been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released in late August, the company found that deal volume in the pharma and life-science industries rose 43.5% over Q2 2013, to a total of 33. The total value of these deals rose 19.8% to $14.5 billion. Scalper1 News
Scalper1 News